Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 55

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 55
---
 and their terms will expire at this Annual Meeting; •the Class II directors are Mr. Atwood and Ms. LaPorte, and their terms will expire at our 2026 annual meeting of stockholders; and •the Class III directors are Mr. Ehrlich and Mr. Patel, and their terms will expire at our 2027 annual meeting of stockholders. Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three -yearterm at the annual meeting of stockholders in the year in which their term expires. Our Certificate of Incorporation and Bylaws provide that the authorized number of directors may be changed only by resolution of our board of directors. Our Certificate of Incorporation also provides that our directors may be removed only for cause by the affirmative vote of the holders of at least two -thirds(2/3) of the outstanding shares then entitled to vote in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Our board of directors has nominated Michael Byrnes and Dr. Lindsey Rolfe for election as the Class I directors at the Annual Meeting. The nominees are presently directors and have indicated a willingness to continue to serve as directors, if elected. If the nominees become unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors. Nominees for Election as Class I Directors The following table and narrative information identify our nominees for Class I directors and sets forth their principal occupation and business experience during the last five years and their ages as of April1, 2025.

| Name                |     | Age |     | Title    |     | Director Since |
| Directors:          |     |     |     |          |     |                |
| Michael Byrnes      |     |  48 |     | Director |     |           2024 |
| Lindsey Rolfe, M.D. |     |  57 |     | Director |     |           2024 |

Michael Byrneshas served as a member of our board of directors since February 2024. Mr. Byrnes has served as the Chief Financial Officer of Fore Biotherapeutics since August 2024. Previously, Mr. Byrnes served as the Chief Financial Officer of eFFECTOR Therapeutics from December 202